Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1503518/000104746915002890/a2223865z10-k.htm
Exhibit 99.1
21ST CENTURY ONCOLOGY HOLDINGS, INC.
21st Century Oncology Contact: |
Investor Contact: |
Richard Lewis |
The Ruth Group |
SVP, CFO for U.S. Operations |
Nick Laudico |
239-931-7281 |
646-536-7030 |
richard.lewis@21co.com |
nlaudico@theruthgroup.com |
|
|
|
Courtney Dugan |
|
646-536-7024 |
|
cdugan@theruthgroup.com |
21ST CENTURY ONCOLOGY HOLDINGS INC. REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS
Fourth Quarter 2014 Highlights:
· Total pro-forma revenues of $269.5 million, a 28.8% year-over-year increase
· 7th consecutive quarter of growth in same store freestanding treatments per day, up 2.3% year-over-year
· 4th consecutive quarter of Pro Forma Adjusted EBITDA margin expansion 13.8% of total pro-forma revenues
· International cases increased 5.0% versus prior year period
· OnCure Holdings, Inc. (Oncure) and South Florida Radiation Oncology (SFRO) continue to perform ahead of expectations
Full Year 2014 Highlights:
· Pro-forma revenues surpass $1.0 billion, increasing 22.5%
· Domestic same store treatments per day increased 2.6%
· International revenues approaching $100 million, cases increased 10.4%
· Pro Forma Adjusted EBITDA of $150.9 million
· Reduced debt by $200 million with proceeds from Canada Pension Plan Investment Board (CPPIB) investment
Recent Developments:
· Entered into new region of Northwestern U.S. through joint venture with Northwest Cancer Clinic, LLC (NWCC) in January, 2015
· SFRO added two centers, enhancing its coordination of care and ability to leverage resources
· Established formal affiliations with the University of Florida (UF) and the University of California Los Angeles (UCLA)
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1503518/000104746915002890/a2223865z10-k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by 21St Century Oncology Holdings, Inc..
21St Century Oncology Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
21St Century Oncology Holdings, Inc. provided additional information to their SEC Filing as exhibits
Ticker: RTSX
CIK: 1503518
Form Type: 10-K Annual Report
Accession Number: 0001047469-15-002890
Submitted to the SEC: Fri Mar 27 2015 5:05:58 PM EST
Accepted by the SEC: Fri Mar 27 2015
Period: Wednesday, December 31, 2014
Industry: Offices And Clinics Of Doctors Of Medicine